1-2 of 2
Authors: Ancilla W Fernandes
Sort by
Journal Article
Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy
Emanuel Lohrmann and others
Clinical Kidney Journal, Volume 18, Issue 3, March 2025, sfaf062, https://doi.org/10.1093/ckj/sfaf062
Published: 25 February 2025
Journal Article
Liver safety of tolvaptan in patients with autosomal dominant polycystic kidney disease: interim data from a post-authorization safety study
Thomas Jaeger and others
Clinical Kidney Journal, Volume 17, Issue 11, November 2024, sfae324, https://doi.org/10.1093/ckj/sfae324
Published: 30 October 2024
Advertisement intended for healthcare professionals
Advertisement intended for healthcare professionals